What n acetyl cysteine doses do labels and studies give?

Strengths and labelled doses
ProductStrengthLabelled dose
NACSYS effervescent tablet (UK)1600 mg per tablet1 effervescent tablet of 600 mg once daily, adults only, as a mucolytic
Acetadote injection (US)4200 mg/mL, 6000 mg in a 30 mL vialAcetaminophen overdose, intravenous: 300 mg/kg in total, as a three-bag regimen over a total of 21 hours (for 41 to 99 kg: 150, 50 then 100 mg/kg) or a two-bag regimen over a total of 20 hours (for 41 to 99 kg: 200 then 100 mg/kg)
Hospira solution, oral (US)510% (100 mg/mL) and 20% (200 mg/mL) in 30 mL vialsAcetaminophen overdose, by mouth, started within 24 hours of ingestion: 140 mg per kilogram, then, if the acetaminophen level is in the toxic range or could not be obtained, 70 mg/kg 4 hours later, repeated at 4-hour intervals for a total of 17 doses
Hospira solution, nebulised (US)5Same vialsInto a face mask, mouth piece or tracheostomy: 1 to 10 mL of 20% or 2 to 20 mL of 10% every 2 to 6 hours; for most patients, 3 to 5 mL of 20% or 6 to 10 mL of 10%, 3 to 4 times a day

The UK NACSYS label gives adults one 600 mg effervescent tablet once daily as a mucolytic, and the COPD trials BRONCUS (Decramer, 2005; 523 patients, 3 years) and PANTHEON (Zheng, 2014; 1006 patients, 1 year) gave 600 mg daily or twice daily against placebo.123

Strengths and labelled doses

The table is set at the top of the page

A DailyMed search for acetylcysteine, cetylev and acetylcysteine effervescent turned up no US label for a supplement-type NAC tablet, capsule or powder. FDA's guidance says NAC is excluded from the dietary supplement definition because NAC was approved as a new drug before it was marketed as a dietary supplement or as a food.6

How NAC is mixed

The UK label says to dissolve each 600 mg effervescent tablet in half a glass of water.1 The Hospira label says an oral overdose dose needs the 20% solution diluted with diet cola or another diet soft drink to a final 5%.5 A search for an oral NAC powder leaflet turned up no mixing instruction.

What trials used

TrialDose and schedulePeopleLength
BRONCUS (Decramer, 2005)2600 mg daily, against placebo523 patients with COPD in 50 centres3 years
PANTHEON (Zheng, 2014)3N-acetylcysteine 600 mg twice daily, against matched placebo1006 patients aged 40 to 80 with moderate-to-severe COPD in China (504 NAC, 502 placebo)1 year
Zhou, mild-to-moderate COPD7600 mg twice daily, against matched placebo968 patients aged 40 to 80 with mild-to-moderate COPDTwo years
PANTHER-IPF (Martinez)8NAC, against placebo264 patients with idiopathic pulmonary fibrosis (133 NAC, 131 placebo), 105 of them added after the three-drug arm ended60 weeks
Gray, adult cannabis use disorder9NAC 1200 mg twice daily, or placebo, each added to contingency management302 treatment-seeking adults aged 18 to 50 (153 NAC, 149 placebo)12 weeks
Gray, youth cannabis use disorder10NAC 1200 mg or placebo twice daily, with weekly medical management and brief behavioural counselling for all192 people aged 14 to 21 (98 NAC, 94 placebo)12 weeks

The schedules differ: once daily on the UK label,1 daily in BRONCUS,2 twice daily in PANTHEON and Zhou37 and 1200 mg twice daily in the cannabis trials.910

Storage

The Acetadote label says to store unopened vials at 20° to 25°C, and that the diluted solution can be stored for 24 hours at room temperature.4 The Hospira label says to store an open vial of undiluted solution in a refrigerator at 2° to 8°C and discard it after 96 hours, and to use dilutions freshly prepared, within one hour.5

A search of DailyMed, the UK label and PubMed turned up no stability data for NAC powder mixed in water for drinking.

Frequently asked questions

How much of an oral NAC dose is absorbed?

In a randomised crossover study by Olsson and colleagues (1988), 6 healthy volunteers got NAC 200 mg intravenously and 400 mg by mouth, and oral bioavailability was 4.0% for reduced NAC and 9.1% for total NAC.11 The terminal half-life was 1.95 h for reduced NAC after the intravenous dose, and for total NAC it was 5.58 h after the intravenous dose and 6.25 h after the oral dose.11 A study by Borgström and colleagues (1986), which gave 10 fasting healthy volunteers a single 600 mg dose, reported a late elimination half-life of 2.27 h and oral availability of between 6 and 10%, lowest for the slow-release tablet and highest for the fast dissolving tablet.12

Can you take NAC before bed?

A PubMed and DailyMed search turned up no label or trial on NAC before bed, or with or without food. The UK label says patients with a reduced cough reflex (elderly and weakened patients) are advised to take the effervescent tablet in the mornings.1

Is there a dose for an NAC cycle or for NAC with NAD?

A search of PubMed, DailyMed and the FDA guidance turned up nothing on an NAC on and off cycle or on NAC dosing with NAD.

References

  1. electronic medicines compendium (UK SmPC). NACSYS 600mg Effervescent Tablets - Summary of Product Characteristics (SmPC) - print friendly - (emc). medicines.org.uk
  2. PubMed. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. 2005. pubmed.ncbi.nlm.nih.gov
  3. PubMed. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. 2014. pubmed.ncbi.nlm.nih.gov
  4. DailyMed. These highlights do not include all the information needed to use ACETADOTE safely and effectively. See full prescribing information for ACETADOTE. ACETADOTE (acetylcysteine) injection, for intravenous use Initial U.S. Approval: 2004. 2025. dailymed.nlm.nih.gov
  5. DailyMed. ACETYLCYSTEINE Solution, USP 10% and 20% Teartop Vials. 2026. dailymed.nlm.nih.gov
  6. US FDA. Guidance for Industry: Policy Regarding N-acetyl-L-cysteine. 2022. fda.gov
  7. PubMed Central. Effect of high-dose N -acetylcysteine on exacerbations and lung function in patients with mild-to-moderate COPD: a double-blind, parallel group, multicentre randomised clinical trial. 2024. pmc.ncbi.nlm.nih.gov
  8. PubMed Central. Randomized Trial of N-acetylcysteine in Idiopathic Pulmonary Fibrosis. 2014. pmc.ncbi.nlm.nih.gov
  9. PubMed Central. A randomized placebo-controlled trial of N -acetylcysteine for cannabis use disorder in adults. 2017. pmc.ncbi.nlm.nih.gov
  10. PubMed Central. N-acetylcysteine for youth cannabis use disorder: randomized controlled trial main findings. 2025. pmc.ncbi.nlm.nih.gov
  11. PubMed. Pharmacokinetics and bioavailability of reduced and oxidized N-acetylcysteine. 1988. pubmed.ncbi.nlm.nih.gov
  12. PubMed. Pharmacokinetics of N-acetylcysteine in man. 1986. pubmed.ncbi.nlm.nih.gov